0.325
0.00 (0.84%)
| Penutupan Terdahulu | 0.322 |
| Buka | 0.322 |
| Jumlah Dagangan | 859,696 |
| Purata Dagangan (3B) | 2,510,210 |
| Modal Pasaran | 17,935,320 |
| Harga / Jualan (P/S) | 0.970 |
| Harga / Buku (P/B) | 3.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| Margin Operasi (TTM) | -375.94% |
| EPS Cair (TTM) | -2.47 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 32.50% |
| Nisbah Semasa (MRQ) | 2.28 |
| Aliran Tunai Operasi (OCF TTM) | -120.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -66.13 M |
| Pulangan Atas Aset (ROA TTM) | -57.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -2,986.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Marinus Pharmaceuticals, Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.94% |
| % Dimiliki oleh Institusi | 83.04% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 4.00 (Cantor Fitzgerald, 1,130.77%) | Beli |
| Median | 2.50 (669.23%) | |
| Rendah | 0.500 (Jefferies, 53.85%) | Pegang |
| Purata | 2.25 (592.31%) | |
| Jumlah | 3 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 0.338 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 Nov 2024 | 4.00 (1,130.77%) | Beli | 0.309 |
| 25 Oct 2024 | 4.00 (1,130.77%) | Beli | 0.405 | |
| HC Wainwright & Co. | 14 Nov 2024 | 2.00 (515.38%) | Pegang | 0.309 |
| D. Boral Capital | 13 Nov 2024 | 3.00 (823.08%) | Beli | 0.302 |
| Jefferies | 25 Oct 2024 | 0.500 (53.85%) | Pegang | 0.405 |
| RBC Capital | 25 Oct 2024 | 1.00 (207.69%) | Pegang | 0.405 |
| EF Hutton | 24 Oct 2024 | 3.00 (823.08%) | Beli | 0.296 |
| 17 Oct 2024 | 23.00 (6,976.92%) | Beli | 1.74 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |